Swiss Software Stock News

Novartis (SWX:NOVN) is back in focus after releasing final two year Phase III data for Fabhalta in IgA nephropathy, which showed clinically meaningful kidney outcomes versus placebo and supports an ongoing FDA priority review. See our latest analysis for Novartis. The Fabhalta readout appears to be feeding into sentiment, with the share price at CHF122.18 and a 90 day share price return of 7.14%. The 1 year total shareholder return of 48.62% contrasts with a more modest 12.61% year to date...

R&S Group Holding (SWX:RSGN) has reported its FY 2025 figures with first half revenue of CHF 206.3 million and basic EPS of CHF 0.77, set against trailing twelve month revenue of CHF 417.7 million and EPS of CHF 1.56 that reflect a 41% earnings increase over the last year. The company has seen revenue move from CHF 172.7 million in the second half of FY 2024 to CHF 206.3 million in the first half of FY 2025, with EPS shifting from CHF 0.86 to CHF 0.77 in those respective periods. This leaves...

Jungfraubahn Holding (SWX:JFN) has just released full year 2025 results together with a higher annual dividend, giving investors fresh information on earnings, cash returns and how the business exited last year. See our latest analysis for Jungfraubahn Holding. The share price reaction has been positive in the short term, with a 5.1% 1 day share price return and 5.7% 7 day share price return. The 1 year total shareholder return of 69.1% reflects much stronger gains over a longer period. If...

SoftwareOne Holding AG has released its 2025 results, reporting sales of CHF 1,243.4 million and net income of CHF 0.9 million, while proposing a reduced CHF 0.15 per share dividend and setting 2026 guidance for mid-single digit constant-currency revenue growth and a 30%–50% adjusted profit pay-out ratio. Alongside these figures, the company announced a leadership change in human resources, with long-time insider Nina Janorschke stepping in as Chief Human Resources Officer, which may help...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Readers hoping to buy Schweiter Technologies AG ( VTX:SWTQ ) for its dividend will need to make their move shortly, as...

Lonza Group AG ( VTX:LONN ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

Readers hoping to buy Julius Bär Gruppe AG ( VTX:BAER ) for its dividend will need to make their move shortly, as the...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Emmi AG...

Roche’s new cobas MPX-E assay and why it matters for shareholders Roche Holding (SWX:ROG) has launched its cobas MPX-E multiplex assay in CE mark countries, offering simultaneous screening for HIV, HCV, HBV and HEV on existing cobas x800 systems to support higher throughput donor testing. See our latest analysis for Roche Holding. Roche’s share price has softened recently, with a 30 day share price return of 10.47% and a year to date share price return of a 0.98% decline, even though the 1...

As European markets experience a positive shift, with the STOXX Europe 600 Index gaining 3.92% amid hopes for a shorter-lived Middle East conflict, investors are keenly observing how energy market volatility and inflation trends might impact dividend stocks. In this context, selecting robust dividend stocks involves considering companies with strong financial health and stable cash flows that can weather economic fluctuations while continuing to provide reliable income streams.

Dividend announcement puts yield in focus for BCGE Banque Cantonale de Genève (SWX:BCGE) has announced an annual dividend of CHF 0.5250 per share, with the stock trading ex dividend on 5 May 2026 and payment scheduled for 7 May 2026. See our latest analysis for Banque Cantonale de Genève. The dividend news follows a strong run in the shares, with a 30 day share price return of 12.38% and a 90 day share price return of 40.48%. The 1 year total shareholder return of 48.30% highlights how...

If you are wondering whether UBS Group's current share price reflects its true worth, you are not alone. That is exactly what this article is here to unpack. UBS Group closed at CHF31.16 recently, with returns of 1.4% over the past 7 days, 4.4% over the past 30 days, a year to date return of negative 18.4%, 39.6% over 1 year, 79.1% over 3 years and 141.6% over 5 years, hinting at shifting expectations around both opportunity and risk. Recent coverage has focused on UBS Group's ongoing...

Wondering if Logitech International at around $73.32 is offering genuine value or just riding sentiment? This article breaks down what the current share price might be implying about the business. The stock has returned 1.3% over the last 7 days and 4.6% over the last 30 days, set against a year to date return of a 7.8% decline and a 25.7% return over 1 year, with a 49.7% return over 3 years and a 21.4% decline over 5 years. Recent coverage has focused on Logitech International as an...

Investors were underwhelmed by the solid earnings posted by SoftwareOne Holding AG ( VTX:SWON ) recently. Our analysis...

If you are wondering whether Novartis at around CHF123 per share still offers value, the key is to look past the headline price and focus on what you are actually getting for each franc invested. The stock has returned 1.9% over the last week, is roughly flat over 30 days, and has delivered 13.5% year to date alongside 43.2% over 1 year, 65.7% over 3 years, and 96.0% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent attention...

Why Nestlé (SWX:NESN) is on investors’ radar today Nestlé (SWX:NESN) continues to attract attention as investors reassess large consumer staples groups, with the share price around CHF 78.37 and recent returns mixed across the past month and past 3 months. See our latest analysis for Nestlé. While the share price is around CHF78.37 with a 90 day share price return of 2.90%, the 1 year total shareholder return of 2.91% decline and 3 year total shareholder return of 24.37% decline point to...

Roche Holding (SWX:ROP) has attracted fresh attention after announcing the cobas MPX-E assay, a CE-marked in vitro test that screens for HIV and multiple hepatitis viruses in a single high-throughput run. See our latest analysis for Roche Holding. Roche’s recent diagnostics launches and R&D investment news arrive while the share price sits at CHF318.0, with a 30 day share price return of a 6.8% decline but a 1 year total shareholder return of 33.17% that points to stronger long term...

As global markets navigate the complexities of Middle East tensions and energy market volatility, major indices like the Nasdaq Composite have shown resilience with notable gains, reflecting a cautiously optimistic sentiment amid geopolitical uncertainties. In such an environment, growth companies with significant insider ownership often attract attention due to their potential for alignment between management and shareholder interests, which can be particularly appealing when navigating...

As European markets navigate through the complexities of Middle East tensions and energy market volatility, recent gains in indices like the STOXX Europe 600 and Germany’s DAX suggest a cautiously optimistic sentiment among investors. In such an environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

As European markets show resilience with the STOXX Europe 600 Index rising by 3.92%, investor sentiment is buoyed by hopes of a shorter-than-expected Middle East conflict and robust gains in major indices like Germany’s DAX and the UK’s FTSE 100. In this environment, growth companies with high insider ownership can offer unique opportunities, as they often signal strong confidence from those closest to the business, aligning their interests with shareholders during volatile times.

What the latest earnings mean for Aevis Victoria Aevis Victoria (SWX:AEVS) has drawn investor attention after releasing full year 2025 results, with higher sales and revenue reported alongside a materially larger net loss and wider loss per share. The company reported sales of CHF 1,132.9 million and revenue of CHF 1,055.06 million for the year ended December 31, 2025. At the same time, Aevis Victoria posted a net loss of CHF 20.11 million, with basic and diluted loss per share from...

Swiss Prime Site (SWX:SPSN) has moved after the company appointed Martina Moosmann as Chief Financial Officer, formalising succession after an interim period and providing investors with fresh information about its senior financial leadership. See our latest analysis for Swiss Prime Site. The appointment appears to have sparked fresh interest, with the share price at CHF138.4 after a 1 day share price return of 1.10% and 7 day share price return of 4.93%. A 90 day share price return of 13.07%...

Roche Holding (SWX:ROP) has received CE marking for its cobas MPX-E assay, enabling simultaneous screening for HIV, hepatitis C, B, and E in blood donations. The company has also launched the cobas eplex RP3 respiratory panel, designed to test for up to 25 respiratory pathogens in a single rapid assay. These diagnostics products target blood safety, laboratory efficiency, and faster respiratory infection diagnosis across clinical settings. Roche Holding, trading at around CHF318.0,...